
MYOV
Healthcare · Biotechnology · $2.62B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 26, 2023 | After the close | -0.47 | -0.59 | -25.5% |
| Oct 26, 2022 | Before the open | -0.49 | -0.47 | +4.1% |
| Jul 27, 2022 | After the close | -0.32 | -0.22 | +31.3% |
| May 10, 2022 | Before the open | -0.57 | -0.63 | -10.5% |
| Jan 26, 2022 | Before the open | -0.61 | -0.68 | -11.5% |
| Oct 26, 2021 | Before the open | -0.38 | -0.23 | +39.5% |
| Jul 28, 2021 | Before the open | -0.34 | -0.67 | -97.1% |
| May 11, 2021 | Before the open | -0.99 | -0.89 | +10.1% |
| Feb 11, 2021 | Before the open | -0.85 | -0.82 | +3.5% |
| Nov 12, 2020 | Before the open | -0.73 | -0.75 | -2.7% |
| Aug 11, 2020 | Before the open | -0.68 | -0.37 | +45.6% |
| May 18, 2020 | After the close | -0.80 | -0.73 | +8.8% |
| Feb 10, 2020 | Before the open | -0.82 |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an…
| -0.96 |
| -17.1% |
| Nov 12, 2019 | Before the open | -0.72 | -0.79 | -9.7% |
| Aug 6, 2019 | After the close | -0.95 | -0.89 | +6.3% |
| May 24, 2019 | After the close | -1.02 | -1.07 | -4.9% |
| Feb 7, 2019 | After the close | -0.98 | -1.04 | -6.1% |
| Nov 8, 2018 | After the close | -0.93 | -0.99 | -6.5% |
| Aug 7, 2018 | After the close | -0.85 | -0.98 | -15.3% |
| Jun 7, 2018 | After the close | -0.75 | -0.81 | -8.0% |
| Feb 13, 2018 | After the close | -0.51 | -0.70 | -37.3% |